BoomRay Pharma and Novartis sign radioligand therapy licensing deal worth up to $900 million

BoomRay Pharma and Novartis signed a licensing deal for radioligand therapy worth up to $900 million, according to a report on the agreement.

Detected & updated continuously · Source: Nebula